Breakout Stocks of Week 36
NASDAQ was up last week (week 35) by 1.55% ending at 15,363.52 points after gaining 234.02 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Intellia Therapeutics Inc NASDAQ:NTLA. This stock has had a buy signal since Aug 20, 2021 when the price was $149.32 and is so far up 18.39% to $176.78. Some other companies are on our watchlist to, among these are Thermo Fisher Scientific Inc NYSE:TMO Uniti Group Inc. NASDAQ:UNIT Cintas Corporation NASDAQ:CTAS and Compound USD Coin CRYPTO:CUSDCUSD which all got a breakout pattern emerging.
| Date | Company | Price | Week 36 |
|---|---|---|---|
| Intellia Therapeutics Inc | $176.78 | $160.67 | -9.11% |
| Thermo Fisher Scientific Inc | $568.11 | $571.96 | 0.678% |
| Uniti Group Inc. | $13.19 | $12.69 | -3.79% |
| Cintas Corporation | $396.53 | $403.71 | 1.81% |
| Compound Usd Coin | $0.0221 | $0.0222 | 0.0978% |
The Intellia Therapeutics Inc stock price gained 1.59% on the last trading day (Friday, 3rd Sep 2021), rising from $174.01 to $176.78. It has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 5.58% from a day low at $170.40 to a day high of $179.90. The price has risen in 7 of the last 10 days and is up by 18.39% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 329 thousand more shares were traded than the day before. In total, 1 million shares were bought and sold for approximately $225.01 million.
On Aug 07, 2023, it was reported that Barclays gave NTLA a "Overweight" grade with a "hold" action.
Intellia Therapeutics Inc holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Intellia Therapeutics Inc:
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
The Thermo Fisher Scientific Inc stock price gained 0.467% on the last trading day (Friday, 3rd Sep 2021), rising from $565.47 to $568.11. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 1.47% from a day low at $560.53 to a day high of $568.80. The price has been going up and down for this period, and there has been a 2.36% gain for the last 2 weeks. Volume fell on the last day by -275 thousand shares and in total, 824 thousand shares were bought and sold for approximately $468.25 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
On Apr 17, 2024, it was reported that HSBC gave TMO a "Buy" grade with a "hold" action.
Thermo Fisher Scientific Inc holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Thermo Fisher Scientific Inc:
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
The Uniti Group Inc. stock price gained 0.534% on the last trading day (Friday, 3rd Sep 2021), rising from $13.12 to $13.19. During the last trading day the stock fluctuated 2.21% from a day low at $12.92 to a day high of $13.20. The price has risen in 6 of the last 10 days and is up by 2.09% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 155 thousand more shares were traded than the day before. In total, 1 million shares were bought and sold for approximately $18.44 million.
On Feb 05, 2024, it was reported that Morgan Stanley gave UNIT a "Underweight" grade with a "hold" action.
Uniti Group Inc. holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Uniti Group Inc.:
Uniti, an internally managed real estate investment trust, is engaged in the acquisition and construction of mission critical communications infrastructure, and is a leading provider of wireless infrastructure solutions for the communications industry. As of September 30, 2020, Uniti owns 6.7 million fiber strand miles and other communications real estate throughout the United States.
The Cintas Corporation stock price gained 0.0378% on the last trading day (Friday, 3rd Sep 2021), rising from $396.38 to $396.53. It has now gained 6 days in a row. It is not often that stocks manage to gain so many days in a row, and falls for a day or two should be expected. During the last trading day the stock fluctuated 0.86% from a day low at $394.69 to a day high of $398.10. The price has risen in 8 of the last 10 days and is up by 1.2% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 18 thousand more shares were traded than the day before. In total, 324 thousand shares were bought and sold for approximately $128.33 million.
On Apr 01, 2024, it was reported that Goldman Sachs gave CTAS a "Buy" grade with a "hold" action.
Cintas Corporation holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Cintas Corporation:
Cintas Corporation provides corporate identity uniforms and related business services primarily in the United States, Canada, and Latin America. It operates through Uniform Rental and Facility Services, First Aid and Safety Services, and All Other segments. The company rents and services uniforms and other garments, including flame resistant clothing, mats, mops and shop towels, and other ancillary items; and provides restroom cleaning services and supplies, as well as sells uniforms. It also offers first aid and safety services, and fire protection products and services. The company provides its products and services through its distribution network and local delivery routes, or local representatives to small service and manufacturing companies, as well as major corporations. Cintas Corporation was founded in 1968 and is headquartered in Cincinnati, Ohio.
The Compound USD Coin cryptocurrency price gained 0.0054% on the last trading day (Friday, 3rd Sep 2021), rising from $0.0221 to $0.0221. During the last trading day the cryptocurrency fluctuated 0.0557% from a day low at $0.0221 to a day high of $0.0222. The price has been going up and down for this period, and there has been a 0.06% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 2 million more shares were traded than the day before. In total, 91 million shares were bought and sold for approximately $2.02 million.
Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for Compound USD Coin cryptocurrency to perform well in the short-term period.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
